Korean J Pathol.  2014 Feb;48(1):1-9.

Guideline Recommendations for Testing of ALK Gene Rearrangement in Lung Cancer: A Proposal of the Korean Cardiopulmonary Pathology Study Group

Affiliations
  • 1Department of Pathology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea. chungjh@snu.ac.kr gklee@ncc.re.kr
  • 2Department of Pathology, Yonsei University College of Medicine, Seoul, Korea.
  • 3Department of Pathology, Inha University School of Medicine, Incheon, Korea.
  • 4Department of Pathology, The Catholic University of Korea College of Medicine, Seoul, Korea.
  • 5Department of Pathology, Keimyung University Dongsan Medical Center, Daegu, Korea.
  • 6Department of Pathology, National Cancer Center, Goyang, Korea. chungjh@snu.ac.kr gklee@ncc.re.kr

Abstract

Rearrangement of anaplastic lymphoma kinase (ALK) gene is the best predictor of response to crizotinib, an ALK tyrosine kinase inhibitor. However, the prevalence of the ALK fusion is low, so accurate patient identification is crucial for successful treatment using ALK inhibitors. Furthermore, most patients with lung cancer present with advanced-stage disease at the time of diagnosis, so it is important for pathologists to detect ALK-rearranged patients while effectively maximizing small biopsy or cytology specimens. In this review, we propose a guideline recommendation for ALK testing approved by the Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists.

Keyword

Anaplastic lymphoma kinase; Gene rearrangement; Lung neoplasms; Guideline

MeSH Terms

Biopsy
Diagnosis
Gene Rearrangement*
Humans
Lung Neoplasms*
Lung*
Lymphoma
Pathology*
Phosphotransferases
Prevalence
Protein-Tyrosine Kinases
Phosphotransferases
Protein-Tyrosine Kinases
Full Text Links
  • KJP
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr